BioMarin, POMBILITI, OPFOLDA, Cipaglucosidase Alfa, Miglustat, Pompe Disease, Late-Onset Pompe Disease, LOPD, Phase 3 Clinical Trial, Enzyme Replacement Therapy, Rare Diseases

San Rafael, California, U.S., October 2, 2026 BioMarin Pharmaceutical Inc. has announced new five-year Phase 3 data supporting the...